A real-world comparison of 618 patients with transthyretin amyloid cardiomyopathy found acoramidis reduced diuretic intensification events by 43% compared to tafamidis (11.8% vs 20.5%), with a 34% reduction in composite heart failure outcomes. Acoramidis achieves over 90% TTR stabilization versus tafamidis's lower stabilization rates. This rare but deadly heart condition occurs when misfolded proteins accumulate in cardiac tissue, leading to progressive heart failure and death. The findings suggest acoramidis may offer superior clinical outcomes for this devastating disease that primarily affects older adults, particularly men. However, significant limitations temper enthusiasm. The study's brief 4-5 month follow-up period provides only a snapshot of what should be lifelong treatment outcomes. The retrospective design using insurance claims data lacks the rigor of randomized trials, and propensity score weighting cannot eliminate all confounding variables. Most critically, this preprint has not undergone peer review, meaning these promising results require independent validation. Given ATTR-CM's poor prognosis and limited treatment options, these early comparative data are encouraging but preliminary.